Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cancer. 2011;2:357-9. Epub 2011 Jun 15.

Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

Author information

1
Dendreon Corporation, Seattle, WA, USA.

Abstract

Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.

KEYWORDS:

metastatic castrate resistant prostate cancer (mCRPC); sipuleucel-T

PMID:
21716715
PMCID:
PMC3119403
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Ivyspring International Publisher Icon for PubMed Central
    Loading ...
    Support Center